Abstract
Introduction Urinary metabolism breakdown products reflect metabolic changes in atherosclerosis-relevant tissues and may contain relevant therapeutic leads. We integrated data on urinary metabolism breakdown products, plasma proteins, atherosclerotic plaque tissue, and single-cell expression to identify druggable metabolic pathways for coronary heart disease (CHD).
Methods Mendelian randomisation was employed to interrogate findings from independent genome-wide association studies on 954 urinary metabolism breakdown products, 1,562 unique proteins, and 181,522 CHD cases, establishing directionally concordant associations. Using the Athero-Express Biobank, concordant plasma proteins were linked to plaque vulnerability using protein and mRNA expression in plaque. Single-cell RNA sequencing data obtained from carotid plaque samples were used to test for differential expression of concordant proteins across plaque cell types.
Results In total, 29 urinary metabolism breakdown products associated with CHD, predominantly originating from amino acid metabolism (n=12) or unclassified origin (n=9). We identified 113 plasma proteins with directionally concordant associations with these urinary metabolism breakdown products and CHD. Of the 110 proteins available in plaque, 16 were associated with plaque vulnerability. This included positive control proteins targeted by drugs indicated for CHD, such as CAH1 (targeted by aspirin), IL6R (targeted by tocilizumab), and AT1B2 (targeted by digoxin), as well as two potential repurposing opportunities C1S (targeted by C1-esterase inhibitor and sutimlimab) and CATH (targeted by bortezomib).
Conclusion We have identified amino acid metabolism as an important contributing pathway to CHD risk and prioritised 16 proteins relevant for CHD with involvement in atherosclerotic plaques, providing important insights for drug development.
Competing Interest Statement
AFS and CF have received funding from New Amsterdam Pharma for unrelated projects. The other authors declare that they have no conflict of interest.
Funding Statement
SD and SAEP are supported by a VIDI Fellowship (project number 09150172010050) from the Dutch Organisation for Health Research and Development (ZonMW) awarded to SAEP. AFS is supported by BHF grant PG/22/10989, the UCL BHF Research Accelerator AA/18/6/34223, MR/V033867/1, the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the EU Horizon scheme (AI4HF 101080430 and DataTools4Heart 101057849). MV is supported by a postdoc talent grant from the Amsterdam Cardiovascular Sciences. This work was funded by UK Research and Innovation (UKRI) under the UK government[prime]s Horizon Europe funding guarantee EP/Z000211/1. This publication is part of the project [Prime]Computational medicine for cardiac disease[Prime] with file number 2023.022 of the research programme [Prime]Computing Time on National Computer Facilities[Prime] which is (partly) financed by the Dutch Research Council (NWO).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The performed study is in line with the Declaration of Helsinki, and informed consent was provided by all study participants after approval for this study by the medical ethical committees of the various hospitals (University Medical Center, Utrecht, The Netherlands, and St. Antonius Hospital, Nieuwegein, The Netherlands) was obtained.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* joint senior author
Data availability
The GWAS data on CHD used in this study can be accessed via https://www.ebi.ac.uk/gwas/studies/GCST90132314 (n=181,522 CHD cases, n=984,168 controls). The GWAS data on urinary metabolism breakdown product values can be accessed via https://www.ebi.ac.uk/gwas/publications/31959995 (n=1,627). The individual GWAS data on plasma protein values can be accessed as follows: deCODE (n=35,559, https://www.decode.com/summarydata/), SCALLOP (n=30,931, https://www.ebi.ac.uk/gwas/publications/33067605), Ahola-Olli et al. (n=8,293, https://www.ebi.ac.uk/gwas/publications/27989323), Framingham (n=6,861, https://www.ebi.ac.uk/gwas/publications/21909115), AGES-Reykjavik (n=5,368, https://www.ebi.ac.uk/gwas/publications/35078996), INTERVAL (n=3,301, https://www.ebi.ac.uk/gwas/publications/29875488), Gilly et al. (n=1,328, https://www.ebi.ac.uk/gwas/publications/33303764), and Yang et al. (n=636, https://www.ebi.ac.uk/gwas/publications/34239129).
